Complications arising from this disease include low flow and obstruction of (*) pancreatic ducts.
A potentiator drug used to treat this disease's Class III type is combined with lumacaftor to form the drug Orkambi, which is used to treat its more common Class II variety. The drug Ivacaftor was the first to treat an underlying molecular defect of this disease. Low alkalinity in epithelial ducts due to this disease leads to low enzyme drainage and therefore abnormally high amounts of IRT, which is used to screen for this disease in babies. Complications arising from this disease include low flow and obstruction of (*) pancreatic ducts. This disease can obstruct sperm ducts, leading to congenital absence of the vas deferens. The most common mutation leading to this disease is a deletion of phenylalanine-508 in a gene coding for a transmembrane regulator named for this disease, leading to reduced osmolarity due to a lack of chlorine ion transport. For 10 points, name this genetic disorder which causes scarring and chronic infection of the airways due to buildup of thick, dehydrated mucus in the lungs.
A potentiator drug used to treat this disease's Class III type is combined with lumacaftor to form the drug Orkambi, which is used to treat its more common Class II variety.
cystic fibrosis [or CF]